fda warning letters compounded semaglutide tirzepatide 2024 2025 Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA takes aim at misleading

To dispose of unused or expired semaglutideincluding Ozempic, Wegovy, and Rybelsus check for local drug take-back programs or collection sites that accept injectable and/or oral medications

This groundbreaking medication has been shown to significantly aid weight loss when combined with lifestyle changes, offering hope to those seeking a sustainable path to a healthier weight

Studies suggest such combination approaches may offer sustained efficacy for addressing skin hyperpigmentation concerns with potentially enhanced tolerability profiles

What Research Says About GLP-1 Medications and Cancer Risk Two kinds of research are part of this conversation: retrospective and prospective studies